(Photo Credits: PTI)
New Delhi, 16 September: Drugs Controller General of India Dr. VG Somani on Tuesday allowed the Serum Institute of India (SII) to resume clinical trials (clinical trials) on candidates for Oxford’s Kovid-19 vaccine. DCGI rescinded its earlier order prohibiting the selection of any candidate for the second and third phase trials.
However, DCGI has kept many other conditions including extra attention during the investigation for this. SII has been asked by DGCI to submit information about treatment as per rules in dealing with adverse situations.
Also read: Corona pandemic: 37 Indians including 363 NORI visa holders stranded in Pakistan due to Corona crisis return to India
Earlier on September 11, DCGI directed the Serum Institute of India to stop the clinical trial of a possible vaccine for Kovid-19 as the pharmaceutical company Astragenica reported ‘ill-health’ of one person involved in the study. Testing was stopped in countries.